Frankfurt - Delayed Quote EUR
Corcept Therapeutics Incorporated (HTD.F)
68.78
+1.18
+(1.75%)
At close: 9:48:34 PM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | 199.39M | 247.54M | 899.05M | 1.22B |
| Low Estimate | 184.58M | 239.15M | 894.2M | 1.03B |
| High Estimate | 210M | 261M | 901.3M | 1.38B |
| Year Ago Sales | 163.8M | 182.55M | 675.04M | 899.05M |
| Sales Growth (year/est) | 21.73% | 35.60% | 33.18% | 35.23% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| HTD.F | -- | -- | -- | -- |
| S&P 500 | 13.07% | 2.27% | 7.37% | 14.07% |
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/6/2025 |
| Maintains | Piper Sandler: Neutral to Neutral | 4/3/2025 |
| Maintains | Piper Sandler: Overweight to Overweight | 4/3/2025 |
| Maintains | Canaccord Genuity: Buy to Buy | 4/1/2025 |
| Maintains | Truist Securities: Buy to Buy | 3/31/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/31/2025 |